Stratifying cancer therapies by molecular interactions and imaging

Myria Galazi; Gregory Weitsman; James Monypenny; Oana Coban; Hanna Milewicz; Valenti Gomez; Francesca Ciccarelli; Tony Ng

doi:10.1007/978-3-319-53661-3_15

Stratifying cancer therapies by molecular interactions and imaging

Myria Galazi, Gregory Weitsman, James Monypenny, Oana Coban, Hanna Milewicz, Valenti Gomez, Francesca Ciccarelli, Tony Ng^*

^*Corresponding author for this work

Cell Imaging

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

1 Citation (Scopus)

Abstract

Accumulated knowledge generated by years of fundamental research and more recently the implementation of high-throughput sequencing analysis and genomic technologies have led to the identification of novel molecular events that are critical oncogenic drivers amenable to targeted therapy. As a result, in the past decade, we have observed the introduction of molecularly targeted therapies for the treatment of cancers within clinical trials that have then subsequently gained approval for use in routine clinical practice. Some of these agents have demonstrated dramatic efficacies, not previously observed in the treatment of metastatic cancers, such as malignant melanoma, non-small cell lung cancer (NSCLC), colorectal cancer and breast cancer.

Original language	English
Title of host publication	Mechanisms of Molecular Carcinogenesis
Publisher	Springer International Publishing Switzerland
Pages	315-358
Number of pages	44
Volume	2
ISBN (Electronic)	9783319536613
ISBN (Print)	9783319536606
DOIs	https://doi.org/10.1007/978-3-319-53661-3_15
Publication status	E-pub ahead of print - 23 May 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/978-3-319-53661-3_15

Cite this

@inbook{5efe0f421f134f2da3e60dd1d3f7e4b1,

title = "Stratifying cancer therapies by molecular interactions and imaging",

abstract = "Accumulated knowledge generated by years of fundamental research and more recently the implementation of high-throughput sequencing analysis and genomic technologies have led to the identification of novel molecular events that are critical oncogenic drivers amenable to targeted therapy. As a result, in the past decade, we have observed the introduction of molecularly targeted therapies for the treatment of cancers within clinical trials that have then subsequently gained approval for use in routine clinical practice. Some of these agents have demonstrated dramatic efficacies, not previously observed in the treatment of metastatic cancers, such as malignant melanoma, non-small cell lung cancer (NSCLC), colorectal cancer and breast cancer.",

author = "Myria Galazi and Gregory Weitsman and James Monypenny and Oana Coban and Hanna Milewicz and Valenti Gomez and Francesca Ciccarelli and Tony Ng",

year = "2017",

month = may,

day = "23",

doi = "10.1007/978-3-319-53661-3_15",

language = "English",

isbn = "9783319536606",

volume = "2",

pages = "315--358",

booktitle = "Mechanisms of Molecular Carcinogenesis",

publisher = "Springer International Publishing Switzerland",

}

TY - CHAP

T1 - Stratifying cancer therapies by molecular interactions and imaging

AU - Galazi, Myria

AU - Weitsman, Gregory

AU - Monypenny, James

AU - Coban, Oana

AU - Milewicz, Hanna

AU - Gomez, Valenti

AU - Ciccarelli, Francesca

AU - Ng, Tony

PY - 2017/5/23

Y1 - 2017/5/23

N2 - Accumulated knowledge generated by years of fundamental research and more recently the implementation of high-throughput sequencing analysis and genomic technologies have led to the identification of novel molecular events that are critical oncogenic drivers amenable to targeted therapy. As a result, in the past decade, we have observed the introduction of molecularly targeted therapies for the treatment of cancers within clinical trials that have then subsequently gained approval for use in routine clinical practice. Some of these agents have demonstrated dramatic efficacies, not previously observed in the treatment of metastatic cancers, such as malignant melanoma, non-small cell lung cancer (NSCLC), colorectal cancer and breast cancer.

AB - Accumulated knowledge generated by years of fundamental research and more recently the implementation of high-throughput sequencing analysis and genomic technologies have led to the identification of novel molecular events that are critical oncogenic drivers amenable to targeted therapy. As a result, in the past decade, we have observed the introduction of molecularly targeted therapies for the treatment of cancers within clinical trials that have then subsequently gained approval for use in routine clinical practice. Some of these agents have demonstrated dramatic efficacies, not previously observed in the treatment of metastatic cancers, such as malignant melanoma, non-small cell lung cancer (NSCLC), colorectal cancer and breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=85033604653&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-53661-3_15

DO - 10.1007/978-3-319-53661-3_15

M3 - Chapter

AN - SCOPUS:85033604653

SN - 9783319536606

VL - 2

SP - 315

EP - 358

BT - Mechanisms of Molecular Carcinogenesis

PB - Springer International Publishing Switzerland

ER -

Stratifying cancer therapies by molecular interactions and imaging

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this